Tag Archives: Boris Peaker

Cowen & Co. Releases a Buy Rating on Surface Oncology Inc (SURF)

In a report released today, Boris Peaker from Cowen & Co. assigned a Buy rating to Surface Oncology Inc (SURF – Research Report). The company’s shares opened today at $5.50, close to its 52-week low of $3.45. According to TipRanks.com,

Cowen & Co. Sticks to Its Hold Rating for Ironwood Pharma (IRWD)

Cowen & Co. analyst Boris Peaker maintained a Hold rating on Ironwood Pharma (IRWD – Research Report) today and set a price target of $16. The company’s shares opened today at $12.90. According to TipRanks.com, Peaker is a 4-star analyst

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clearside Biomedical (NASDAQ: CLSD) and Avrobio Inc (NASDAQ: AVRO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Clearside Biomedical (CLSD – Research Report) and Avrobio Inc (AVRO – Research Report). Clearside Biomedical (CLSD) In a report released today, Boris Peaker from Cowen

Heron Therapeutics (HRTX) Received its Third Buy in a Row

After Cantor Fitzgerald and Needham gave Heron Therapeutics (NASDAQ: HRTX) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Boris Peaker reiterated a Buy rating on Heron Therapeutics today and set a

Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX), BeiGene Ltd (NASDAQ: BGNE) and Agios Pharma (NASDAQ: AGIO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Argenx Se (ARGX – Research Report), BeiGene Ltd (BGNE – Research Report) and Agios Pharma (AGIO – Research Report) with bullish sentiments.

Cowen & Co. Reaffirms Their Hold Rating on Emergent Biosolutions (EBS)

Cowen & Co. analyst Boris Peaker maintained a Hold rating on Emergent Biosolutions (EBS – Research Report) today and set a price target of $64. The company’s shares closed yesterday at $69.70, close to its 52-week high of $71.77. According